Stefano Barco, Saverio Virdone, Andrea Götschi, Walter Ageno, Juan I Arcelus, Roland Bingisser, Giuseppe Colucci, Frank Cools, Daniel Duerschmied, Harry Gibbs, Riccardo M Fumagalli, Bernhard Gerber, Sylvia Haas, Jelle C L Himmelreich, Richard Hobbs, Lukas Hobohm, Barry Jacobson, Gloria Kayani, Renato D Lopes, Peter MacCallum, Evy Micieli, Marc Righini, Helia Robert-Ebadi, Ana Thereza Rocha, Thomas Rosemann, Jitendra Sawhney, Sebastian Schellong, Tim Sebastian, David Spirk, Stefan Stortecky, Alexander G G Turpie, Davide Voci, Nils Kucher, Karen Pieper, Ulrike Held, Ajay K Kakkar
BACKGROUND: Antithrombotic treatment may improve the disease course in non-critically ill, symptomatic COVID-19 outpatients. METHODS: We performed an individual patient-level analysis of the OVID and ETHIC randomized controlled trials, which compared enoxaparin thromboprophylaxis for either 14 (OVID) or 21 days (ETHIC) vs. no thromboprophylaxis for outpatients with symptomatic COVID-19 and at least one additional risk factor. The primary efficacy outcome included all-cause hospitalization and all-cause death within 30 days from randomization...
August 18, 2023: Thrombosis Research